Aclarion, Inc. (NASDAQ:ACON) Short Interest Down 26.6% in December

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 31,021 shares, a drop of 26.6% from the December 15th total of 42,256 shares. Based on an average daily volume of 105,445 shares, the days-to-cover ratio is presently 0.3 days. Currently, 4.7% of the shares of the stock are sold short. Currently, 4.7% of the shares of the stock are sold short. Based on an average daily volume of 105,445 shares, the days-to-cover ratio is presently 0.3 days.

Aclarion Trading Down 5.3%

Aclarion stock opened at $3.79 on Friday. Aclarion has a 12-month low of $3.68 and a 12-month high of $692.85. The firm has a 50-day moving average price of $5.86 and a 200-day moving average price of $6.99. The firm has a market capitalization of $3.22 million, a PE ratio of -0.25 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. As a group, sell-side analysts predict that Aclarion will post -263.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ACON has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Aclarion to a “hold” rating in a research report on Saturday, December 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.